Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Editas Stock Isn't Worth Buying This Early Into Treatment Development
10:10am, Wednesday, 21'st Jul 2021
EDIT stock is part of a pioneering movement in CRISPR gene editing, but there's no way to know whether the company will succeed long term. The post Editas Stock Isn't Worth Buying This Early Into Trea
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
11:02am, Friday, 16'th Jul 2021
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.
The Top 3 Gene Editing Stocks to Own for the Next Decade
01:03pm, Monday, 12'th Jul 2021
Gene editing could revolutionize the way we treat diseases. Along the way, it could also create substantial opportunity for related stocks.
Caribou Bioscience: Gene Editing Pioneer Files IPO To Raise $100M
05:16am, Sunday, 11'th Jul 2021
Caribou Bioscience: Gene Editing Pioneer Files IPO To Raise $100M
IDNA: Genetics Now Have A Lot Of Influence On Healthcare
03:12am, Saturday, 10'th Jul 2021
IDNA: Genetics Now Have A Lot Of Influence On Healthcare
A Comprehensive Guide to Genomic ETFs
05:17pm, Friday, 09'th Jul 2021
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Do Options Traders Know Something About Editas Medicine (EDIT) Stock We Don't?
09:46am, Wednesday, 07'th Jul 2021
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Here's What Drove Gene Editing Stocks Higher This Week
12:48pm, Friday, 02'nd Jul 2021
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
07:30am, Thursday, 01'st Jul 2021
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest S
Editas Medicine: An Undervalued, Gene-Editing Stock
07:04am, Thursday, 01'st Jul 2021
The rally for gene-editing stocks has entered its third day.
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
02:12pm, Wednesday, 30'th Jun 2021
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia. The post Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
02:04pm, Wednesday, 30'th Jun 2021
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
The 3 Biotech Firms Riding High on CRISPR News
01:37pm, Wednesday, 30'th Jun 2021
Biotech stocks can be risky. If a clinical trial fails, you could very well lose your money.
CRISPR: 4 Emerging Players
09:06am, Wednesday, 30'th Jun 2021
CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agr
EDIT Stock Price Increases Over 5%: Why It Happened
03:08pm, Monday, 28'th Jun 2021
The stock price of Editas Medicine Inc (NASDAQ: EDIT) increased by over 5% during intraday trading. This is why it happened.
